Did Insulet beat or miss consensus estimates last quarter?

What were the key takeaways from Insulet's earnings call?

What guidance did Insulet's management provide for the next earnings period?

What factors drove the changes in Insulet's revenue and profit?

What is Insulet's gross profit margin?

What is the market's earnings forecast for Insulet next quarter?

What were the key takeaways from Insulet’s earnings call?

What is Insulet's latest dividend and current dividend yield?

- **Revenue Growth**: 23% YoY (constant currency), driven by Omnipod demand and type 2 customer expansion.
- **Type 2 Challenges**: Lower retention/utilization in first 90 days; actions include enhanced support, sales incentives, and Omnipod Discover platform.
- **Financial Strength**: Adjusted EPS up 41.5%, free cash flow $145M YTD, and 19.3% operating margin.
- **Updated Outlook**: 2026 revenue 20%-22%, EPS growth >30%, with cautious 2027 assumptions reflecting execution focus.
- **Innovation Edge**: Omnipod 6 adoption strong; fully closed-loop system for type 2 expected in 2027.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue grew 23% year-over-year (constant currency), driven by strong demand for Omnipod in both U.S. and international markets. U.S. Omnipod revenue increased 20%, while international Omnipod revenue rose 35% (reported basis). Global new customer starts rebounded sequentially, reaching the second-highest quarter ever, with type 2 diabetes customers representing over 40% of new starts.
- **Challenges in Type 2 Market**: Lower utilization and retention rates among type 2 customers were identified, particularly in the first 90 days of therapy. Actions include expanding customer care teams, adjusting sales force incentives to prioritize retention, refining sampling programs, and launching the Omnipod Discover platform to improve onboarding support.
- **Innovation Pipeline**: Omnipod 6 algorithm enhancements are gaining traction, and the fully closed-loop system for type 2 diabetes (Evolve study) is progressing, with a 510(k) submission expected in 2027. International expansion continued with launches in Spain and strong performance in Australia.
- **Updated Outlook**: Full-year 2026 revenue guidance revised to 20%-22% growth (total company), with U.S. Omnipod growth at 17%-19% and international Omnipod growth at 30%-32% (constant currency). Adjusted EPS expected to grow at least 30%.

**【CFO Financial Commentary】**
- **Financial Performance**: Q2 revenue reached $802 million (23.5% YoY growth), with adjusted EPS of $1.66 (41.5% YoY increase). Adjusted gross margin improved to 72.9% due to manufacturing productivity and pricing. Operating margin expanded 140 basis points to 19.3%.
- **Cash Flow**: Generated $145 million in free cash flow year-to-date, supporting investments in manufacturing and growth initiatives. Ended the quarter with $535 million in cash and investments.
- **Guidance Details**: Third-quarter revenue growth expected at 17.5%-19.5% (total company), with U.S. Omnipod growth of 14%-16%. Full-year operating margin expansion target remains 100 basis points, with EPS growth exceeding 30%.

**【Q&A Highlights】**
- **Type 2 Retention Insights**: Early data shows improved retention with Omnipod Discover, but challenges persist in the first 90 days. Actions to enhance customer support and sales force incentives are expected to yield results in 2027.
- **Competition and Pricing**: Assumptions for 2027 include stable pricing and competition from new entrants. Insulet maintains confidence in its differentiated form factor and innovation pipeline.
- **Long-Term Confidence**: CEO emphasizes long-term opportunity in AID adoption, with 5% penetration of eligible U.S. type 2 diabetes patients. Fully closed-loop system for type 2 is seen as a game-changer for retention and utilization.

PODD

PODD

Insulet (PODD) Financials Overview

PODD Q2 2026 Earnings

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Income Statement

Trend

Breakdown

Balance Sheet

Trend

Breakdown

Cash Flow

Trend

Breakdown

Revenue Breakdown

By Business

By Region

Dividend

Payout Ratio

Dividend Yield

You can ask Aime